EP3626270

NOVARTIS AG
Application Number
EP19202854A
Filing Date
Aug 26, 2014
Status
Granted And Under Opposition
Sep 8, 2023
Grant Date
Oct 11, 2023
External Links
Slate, Register

Biblio Summary

The patent EP3626270B1 was granted on Oct 11, 2023 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 16 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ELPEN PHARMACEUTICAL CO. INC.Jul 11, 2024ADMISSIBLE
GENERICS UKJul 11, 2024ADMISSIBLE
LANYON OPPOSITIONS LIMITEDJul 11, 2024ADMISSIBLE
ZENTIVA K.S.Jul 11, 2024ADMISSIBLE
BULLE DR., JANJul 10, 2024ADMISSIBLE
CAMULON LIMITEDJul 10, 2024ADMISSIBLE
DR. SCHON, NEYMEYR & PARTNER PATENTANWALTE MBBJul 10, 2024ADMISSIBLE
SYNTHON BVJul 10, 2024ADMISSIBLE
TEVAJul 10, 2024ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE UND RECHTSANWALT PARTG MBBJul 10, 2024ADMISSIBLE
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Jul 10, 2024ADMISSIBLE
HOFFMANN EITLE PATENT- UND RECHTSANWALTE PARTNERSCHAFTSGESELLSCHAFT MBBJul 9, 2024ADMISSIBLE
EGIS GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAGJul 8, 2024ADMISSIBLE
HAMM&WITTKOPP PATENTANWALTE PARTMBBJul 5, 2024ADMISSIBLE
BETAPHARM ARZNEIMITTEL GMBHJul 2, 2024ADMISSIBLE
ALFRED E. TIEFENBACHER (GMBH & CO. KG)Jun 25, 2024ADMISSIBLE

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245